Condition (MeSH)
Nociceptive Pain
ClinicalTrials.gov lists 146 trials for Nociceptive Pain or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
95 of the 146 trials are tagged with Nociceptive Pain itself; the rest are tagged with a narrower condition beneath it.
When did Nociceptive Pain trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 15
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 10 |
| 2025 | 12 |
| 2024 | 14 |
| 2023 | 12 |
| 2022 | 14 |
| 2021 | 10 |
| 2020 | 14 |
| 2019 | 7 |
| 2018 | 15 |
| 2017 | 7 |
Showing 10 of 22 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 12 trials starting in 2026 and about 13 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 18 trials still running at the 2026-10-09 snapshot; registered median of 10 months across 90 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Nociceptive Pain trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 6 |
| Phase 3 | 5 |
| Phase 4 | 13 |
| Not applicable | 77 |
| Observational | 36 |
How many Nociceptive Pain trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 8 |
| Recruiting | 14 |
| Active, not recruiting | 2 |
| Completed | 82 |
| Suspended | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Nociceptive Pain trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Cara Therapeutics, Inc. | 2 |
| Centrexion Therapeutics | 2 |
| Grünenthal GmbH | 2 |
Which drugs are being tested for Nociceptive Pain? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Remifentanil | 4 |
| DEXMEDETOMIDINE | 3 |
| Oxycodone | 3 |
| Esmolol | 3 |
| PROPOFOL | 3 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| PO Morphine | 3 |
| 18F-FTC-146 | 3 |
| High-dose anrikefon | 2 |
| Medium-dose anrikefon | 2 |
| 1% Sevoflurane | 2 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Nociceptive Pain trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Drug withdrawal syndrome | 2 | 1 |
| Mental Status Changes | 2 | 1 |
| Sedation | 2 | 2 |
| Abdominal pain | 1 | 1 |
| Anaemia Postoperative | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Nociceptive Pain? (71)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Differential relationships between physical activity and pain phenotypes in individuals with spinal cord injury. | The journal of spinal cord medicine | 2025 | Yes |
| Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms. | Nature reviews. Neurology | 2024 | Yes |
| Burst Transspinal Magnetic Stimulation Alleviates Nociceptive Pain in Parkinson Disease-A Pilot Phase II Double-Blind, Randomized Study. | Neuromodulation : journal of the International Neuromodulation Society | 2023 | Yes |
| Development of a tool for objectively measuring somatic pain in the low back region based on a longitudinal diagnostic study conducted in Karachi, Pakistan. | BMJ open | 2023 | Yes |
| Pain response to cannabidiol in induced acute nociceptive pain, allodynia, and hyperalgesia by using a model mimicking acute pain in healthy adults in a randomized trial (CANAB I). | Pain | 2022 | Yes |
Showing 5 of 71 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.